Romanos Sklavenitis‐Pistofidis

Author

Also Known As

A. Bikos, R. Sklavenitis-Pistofidis, Romanos Sklavenitis-Pistofidis, Romanos Sklavenitis‐Pistofidis, Sklavenitis-Pistofidis Romanos

184

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Broad Institute Massachusetts General Hospital Mayo Clinic in Arizona

About

Romanos Sklavenitis‐Pistofidis is an author at Dana-Farber Cancer Institute specializing in immunology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	598
2	Cell Biology	4	4	542
3	Health Sciences	1	1	160
4	Allergy	1	1	56
5	Blood Transplantation	1	1	160

Romanos Sklavenitis‐Pistofidis

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma Oksana Zavidij, Nicholas J. Haradhvala, Tarek H. Mouhieddine, Nature Cancer Hematological MalignancySingle Cell SequencingMedicineImmunologyPathology	2020	341
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Jihye Park, Journal of Clinical Oncology	2020	177
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant Tarek H. Mouhieddine, Adam S. Sperling, Robert Redd, Nature Communications Mixed-phenotype Acute LeukemiaImmunologyPathologyTumor BiologyMyeloid Neoplasia	2020	160
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma Irene M. Ghobrial, Chia‐Jen Liu, Robert Redd, Clinical Cancer Research	2019	97
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Prashant Kapoor, Journal of Clinical Oncology	2019	96
Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis Rebecca Boiarsky, Nicholas J. Haradhvala, Jean-Baptiste Alberge, Nature Communications	2022	61
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma Romanos Sklavenitis‐Pistofidis, Michelle P. Aranha, Robert Redd, Cancer Cell Immune BiomarkersHematological MalignancyCancer ImmunosurveillanceAllergyAutoimmune Disease	2022	56
Progression signature underlies clonal evolution and dissemination of multiple myeloma Yu J. Shen, Yuji Mishima, Jiantao Shi, Blood	2020	48
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology Ankit K. Dutta, Jean-Baptiste Alberge, Elizabeth D. Lightbody, Cancer Discovery	2022	33
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes Mark Bustoros, Shankara Anand, Romanos Sklavenitis‐Pistofidis, Nature Communications	2022	30

Page 1